NHS England’s June 2026 Integrated Performance Report showed a clear improvement in elective care using March 2026 data. The total waiting list had fallen. Referral to Treatment performance had improved. Long waits had reduced. The children and young people’s elective waiting list was also moving in the right direction.

That was a meaningful signal. After several years in which elective recovery has been one of the most visible measures of NHS pressure, the March data showed that targeted focus, validation, oversight and additional activity can shift national performance.

But the April 2026 RTT refresh, published shortly after the June Board meeting, shows why that improvement should be treated as fragile rather than settled. The total waiting list rose again to 7.22 million, up by 112,096 pathways in one month. The proportion of patients waiting within 18 weeks slipped from 65.3% to 65.0%. The number waiting more than 52 weeks increased from 94,406 to 99,781.

The year-on-year position remains better than April 2025, particularly for long waits. But the month-on-month deterioration changes the interpretation. March now looks less like a secure recovery trend and more like a performance gain that needs sustained pathway capacity, diagnostic flow and operational discipline to hold.

The central message is therefore more cautious: elective recovery can be moved, but it is not yet secure. Diagnostics remains a critical bottleneck, and the April RTT rebound shows how quickly headline progress can weaken when demand, backlog and capacity remain finely balanced.

Reading the access data in context

The March 2026 access data was an important signal of progress, but it should not be read as a complete measure of patient experience or underlying capacity.

Elective waiting-list reductions can reflect several things at once: patients being treated, pathway validation, administrative correction, removals where patients no longer require treatment, and operational grip on long waits. These are legitimate parts of waiting-list management, but they mean headline reductions should not be interpreted as treatment activity alone.

There is also an incentive context. NHS England’s Elective Care Capital Incentive Scheme is designed to reward providers that make significant improvements in their Referral to Treatment position while continuing to reduce the waiting list, including long waits. That policy aim is understandable: it creates a financial incentive for providers to improve access and maintain grip on waiting lists. The trade-off is that reported improvement needs careful interpretation. The question for leaders is whether progress reflects sustained pathway capacity, stronger list management, or both.

The April RTT refresh reinforces that caution. Board papers are necessarily a snapshot of the data available at the time. The June Board pack reported the March position, which was positive. But the refreshed April data, published shortly afterwards, showed the waiting list increasing again, 18-week performance slipping, and long waits rising month-on-month.

The wider access picture is therefore positive, but incomplete. Elective performance improved in March and remains better than a year earlier on several key measures. But diagnostics, cancer pathways, community waits, urgent care pressure and provider-level variation continue to shape what patients actually experience.

Urgent and emergency care should also remain part of that wider access context. Performance can move in the right direction against headline measures while long waits, corridor care and exit block remain serious local concerns. Recent HSJ reporting, citing the first official statistics on the scale of corridor care, reported more than 90,000 corridor care cases in English NHS hospitals in May 2026. That reinforces why headline access metrics should be read alongside patient-facing pressure in urgent care and flow.

April RTT refresh shows why the March improvement was fragile

The April 2026 RTT data changes the access narrative.

The June Board papers reported the March 2026 position, which showed a falling elective waiting list, improved 18-week performance and fewer long waits. That was a legitimate Board-level improvement signal. However, the RTT dashboard refreshed on 11 June 2026 showed that the total waiting list increased again in April to 7.22 million, a rise of 112,096 pathways in one month.

The 18-week position also slipped. The proportion of patients waiting within 18 weeks fell from 65.3% in March to 65.0% in April. Long waits also increased, with pathways waiting more than 52 weeks rising from 94,406 to 99,781.

The deterioration was also visible in longer wait categories. Pathways waiting more than 65 weeks increased from 4,342 to 5,776, a rise of 33.0% in one month. Pathways waiting more than 78 weeks increased from 1,047 to 1,145. Pathways waiting more than 104 weeks increased from 154 to 191.

This does not erase the year-on-year improvement. The total waiting list was still lower than April 2025, 18-week performance remained materially better than a year earlier, and waits over 52 weeks were still almost half the level seen the previous year. But it does challenge any simple interpretation that elective recovery had become self-sustaining.

The April refresh reinforces the need to treat Board-paper performance data as a snapshot. March showed what targeted focus and operational grip can achieve. April showed how quickly progress can soften when underlying demand, diagnostic capacity, workforce pressure and pathway constraints remain unresolved.

March showed improvement, but April tested the recovery trend

The Integrated Performance Report records the total elective waiting list at 7.11 million in March 2026. This represented a 1.5% reduction from February 2026 and a 4.2% reduction from March 2025.

Referral to Treatment performance also improved. In March 2026, 65.3% of elective patients were waiting less than 18 weeks, compared with 59.8% in March 2025. NHS England notes that this exceeded the March 2026 ambition of 65%.

Long waits also reduced in March. The percentage of elective pathways waiting more than 52 weeks fell to 1.33%, compared with 1.70% in February 2026 and 2.43% in March 2025.

However, the April RTT refresh shows that this improvement was not yet secure. The total waiting list rose to 7.22 million, 18-week performance slipped to 65.0%, and the number of pathways waiting more than 52 weeks increased to 99,781. The annual position remained better, but the month-on-month movement shows that elective recovery remains vulnerable to demand, capacity and pathway constraint.

For patients, this distinction matters. A single month of improvement can reduce pressure, but sustained recovery depends on whether gains are maintained over time. For provider leaders, the April data reinforces the need to test whether waiting-list reductions are being driven by durable treatment capacity, pathway flow and diagnostic throughput, or by short-term sprint activity and validation.

The improvement should also be interpreted alongside the way elective performance is managed. Waiting-list validation is an important part of maintaining accurate RTT data and ensuring that patients remain on the correct pathway. It can remove duplication, correct pathway errors and identify patients who no longer need treatment. That improves data quality and can reduce the reported list, but it is not the same as expanding clinical capacity.

For that reason, the access signal is strongest when waiting-list reductions are matched by evidence of sustained treatment activity, diagnostic flow and reduced variation between providers.

Diagnostics is constraining the recovery pathway

The strongest counter-signal in the access data is diagnostics.

In March 2026, 21.2% of patients were waiting more than six weeks for one of the key diagnostic tests. NHS England’s diagnostic waiting times report shows this represented 406,900 patients waiting six weeks or more, against an operational standard of less than 1%.

The position was 1.0 percentage point worse than February 2026 and 2.8 percentage points worse than March 2025. None of the seven NHS England regions met the 1% operational standard. Regional performance also varied significantly, with the proportion of patients waiting six weeks or more ranging from 12.7% in the North West to 29.8% in the East of England.

NHS England’s explanation is important. The report states that diagnostic investments supported significant increases in activity, with 29.9 million tests delivered against a 29.1 million target. However, waiting-list growth outstripped activity growth, and the total diagnostic waiting list increased to 1.9 million.

Wider reporting has reinforced the same point. The diagnostic waiting list was reported at around 1.92 million in March 2026, with more than 400,000 patients waiting longer than six weeks despite record diagnostic activity. This supports the Board pack’s central warning: activity is increasing, but not quickly enough to absorb demand and backlog growth.

This is the key operational point. Diagnostic performance can deteriorate even when activity increases, if demand and backlog growth move faster than capacity. That makes diagnostics a system bottleneck rather than a narrow service-line issue.

The impact reaches across the planned care pathway. Timely diagnostics are needed for triage, clinical decision-making, treatment planning, cancer pathways, outpatient productivity, pre-operative assessment and discharge from follow-up. If diagnostic waits lengthen, elective recovery can become slower, less predictable and more resource intensive.

Cancer recovery depends on diagnostic capacity

The cancer data reinforces the same signal.

The Faster Diagnosis Standard was 79.4% in March 2026, narrowly below the 80% operational standard introduced from April 2026. Cancer 62-day performance improved to 72.8% in March 2026, but remained below the 2025/26 planning target of 75%.

NHS England identifies several levers for recovery, including maximising elective and diagnostic capacity to meet cancer demand, improving breast and skin pathways, using Cancer Alliances under the new operating model, and maintaining focus on outliers.

This is a significant Board-level acknowledgement. Cancer pathway improvement is not only about specialist treatment capacity. It also depends on diagnostics, histopathology turnaround, imaging, endoscopy, booking, administrative flow and the ability to identify and act on pathway variation.

The patient impact is direct. Where diagnostic capacity is constrained, patients may wait longer for a definitive diagnosis, treatment planning may be delayed, and pathway uncertainty may increase. Even where performance improves nationally, variation between providers can still mean very different patient experiences.

Capacity must be targeted, not generic

The June Board papers point to a more disciplined model of elective recovery. NHS England references validation incentivisation, national and regional oversight through tiering, a Q4 performance sprint, Getting It Right First Time support, provider-level modality deep dives and demand optimisation initiatives.

This suggests a shift away from broad activity increases towards more targeted operational improvement. The question is no longer simply whether more activity can be delivered, but whether the activity addresses the constraint that is actually delaying the patient pathway.

That matters for clinical capacity planning. Extra sessions, additional clinics, diagnostic lists or theatre activity will have limited impact if they are not aligned to the specific bottleneck. For some providers, the binding constraint may be imaging. For others it may be endoscopy, outpatient review, theatre utilisation, pre-assessment, histopathology, administrative validation or discharge from follow-up.

This also matters for temporary and additional clinical capacity. Where insourcing, mutual aid or additional lists are used, their value depends on whether they are targeted to a proven bottleneck and clinically governed as part of the wider pathway. Additional activity that is not linked to diagnostic flow, decision-making or treatment conversion may improve volume without resolving delay.

The April RTT data makes this point sharper. A short-term performance improvement can be achieved through focused effort, but sustaining it requires capacity that is matched to the pathway constraint. If the underlying bottleneck remains, the system may see improvement in one month and deterioration the next.

The system implication is that elective recovery requires pathway-level precision. Capacity must be clinically governed, data-led and connected to the metric it is intended to improve.

Community waits are part of the access picture

The elective and diagnostic story should not be viewed only through the acute provider lens.

The Integrated Performance Report also shows 89,630 community health service waits of more than 52 weeks in March 2026. This was lower than February 2026, but 15.3% higher than March 2025. NHS England reports that most of these waits were concentrated in community paediatrics, with further waits in children and young people’s speech and language therapy and adult weight management and obesity services.

This matters because planned care recovery is increasingly linked to the wider shift towards neighbourhood, community and preventative care. If community services are unable to absorb demand, patients may remain in acute pathways for longer, present later, or experience fragmented care.

The long-term direction of travel is clear: more care closer to home, more prevention, more community-based support and better flow between settings. But that shift requires real capacity, workforce, data and operational grip. Without it, pressure is displaced rather than resolved.

What this means now

The June Board data gave NHS leaders a positive access signal. The April RTT refresh made that signal more fragile.

March showed that elective performance can improve when national focus, oversight, validation and operational delivery align. But April showed that the improvement was not yet self-sustaining. The total waiting list rose again, 18-week performance slipped, and waits over 52 weeks increased month-on-month.

That does not remove the year-on-year progress. The total waiting list remained lower than April 2025, 18-week performance remained better than a year earlier, and long waits over 52 weeks were still substantially lower than the previous year. It does, however, change the tone. Elective recovery should now be described as fragile, conditional and dependent on sustained capacity rather than as a straightforward improvement trend.

Diagnostics remains the critical bottleneck. The deterioration in six-week waits, despite increased activity, indicates that capacity and demand remain out of balance. Cancer recovery, elective productivity and patient experience will all be affected if this gap is not addressed.

The wider context matters. Headline elective recovery reflects a mix of treatment activity, validation, pathway management and targeted oversight. That does not undermine the improvement, but it does mean the improvement needs to be tested against underlying capacity, diagnostic flow and patient-facing outcomes.

For provider and system leaders, the practical task is to identify the true bottleneck in each pathway and match capacity to it. That means using data to distinguish between theatre constraint, diagnostic constraint, outpatient constraint, workforce constraint and administrative delay. It also means ensuring that additional capacity is clinically appropriate, financially disciplined and capable of showing measurable impact.

For patients, the opportunity is shorter waits and more predictable care. The risk is that progress remains uneven, with diagnostic delay or wider pathway pressure becoming the point at which access improvement slows or reverses.

The forward outlook is therefore cautious and conditional. March showed that elective recovery can move. April showed how quickly it can weaken. Sustaining recovery will depend on whether diagnostic capacity, cancer pathway flow, community access and provider-level variation can now be brought into the same recovery discipline.

References

• NHS England, Integrated Performance Report, June 2026.
• NHS England, Meeting of the Board of NHS England – Agenda, 4 June 2026.
• NHS England, Risk Management, 4 June 2026.
• NHS England, Month 12 Financial Position 2025/26, 4 June 2026.
• NHS England, Board Committee Updates – National Quality Board and Quality Committee, 4 June 2026.
• NHS England, Diagnostic Waiting Times and Activity Report, March 2026.
• NHS England, Referral to Treatment Waiting Times, March 2026.
• NHS England, Referral to Treatment Waiting Times Dashboard, April 2026, refreshed 11 June 2026.
• NHS England, Elective Care Capital Incentive Scheme: Returning to the RTT Standard.
• Health Foundation, NHS Hits Headline Waiting Times Milestone But Other Targets Fall Short, May 2026.
• Nuffield Trust, NHS Performance Dashboard.
• Royal College of Surgeons of England, Waiting-Time Target Met, But Capital Investment Needed to Sustain Progress, May 2026.